CHANGZHI, China.–Deputy Prime Minister Eduardo Martínez Díaz described the inauguration of the Biopharmaceutical Research Institute belonging to the Cuban-Chinese joint venture Biotech Pharmaceutical as a milestone for joint research between Cuba and China. The institute aims to use Chinese technology to create innovative products for cancer immunotherapy and neurodegenerative and autoimmune diseases.
During a tour of the facility, Martínez Díaz highlighted that, thanks to the ties of friendship and mutual assistance between the two countries, Cuba has received around $200 million.
He explained that this amount has been used primarily to purchase raw materials for the production of medicines in the country, as well as to promote research and development projects.
He pointed out that, at present, there are more than ten production facilities in China—some Chinese-owned and others joint ventures—where genetic products are being manufactured for use in our basic range of medicines.
He added that Cuba has ventured into comprehensive solid waste management, as well as projects related to telecommunications and telemedicine.
For the next stage, he reported, it was agreed to work on the creation of the first digital hospital in Cuba.
